News & Updates

Treatment with dapagliflozin leads to a reduction in the rate of total heart failure (HF) events and cardiovascular death, irrespective of patient characteristics such as ejection fraction (EF), according to data from the DELIVER* trial.

Treatment with dazodalibep, a novel nonantibody fusion protein that acts as an antagonist of CD40 ligand, significantly reduced symptom burden in adults with Sjögren’s syndrome, according to the ALISS trial presented at EULAR 2023.

In the treatment of chronic glucocorticoid users with high fracture risk, romosozumab yields higher gains in spine bone mineral density (BMD) compared with denosumab, as shown in a pilot trial presented at EULAR 2023.

Use of mifepristone in the treatment of patients with adenomyosis appears to be safe and efficacious, reducing pain and inducing dysmenorrhea remission, as reported in a study.

Treatment with secukinumab (SEC) shows no significant difference with adalimumab biosimilar (SDZ-ADL) in spinal radiographic progression, which remains low over 2 years, among patients with radiographic axial spondyloarthritis (r-axSpA), according to a phase IIIb study presented at EULAR 2023.